Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Thrombophylaxis in Transurethral Surgery With Dalteparine

This study has been completed.
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: April 21, 2008
Last updated: May 19, 2008
Last verified: May 2008
The rationale for thrombophrophylaxis is well known. Without prophylaxis the incidence of objectivlely confirmed, hospital-acquired deep venous thrombosis is approximately 10% to 40% among medical or general surgical patients. In urology the prevalence is 15-40%. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy1 recommend against specific prophylaxis in patients undergoing transurethral procedures. Our study is the first double-blind, placebo-controlled study with Dalteparine as thrombophrophylaxis in transurethral surgery. The aim of the study is to proof that thrombophrophylaxis causes not more complications in transurethral surgery than without.

Condition Intervention
Thrombophylaxis in Transurethral Surgery
Drug: dalteparine (Fragmin)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Thromboseprophylaxe Mit Niedermolekularem Heparin Bei Transurethralen Eingriffen

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Blood loss [ Time Frame: intraoperativ, 6 hours post op and 3 days postop ]

Enrollment: 250
Study Start Date: June 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
5000IE dalteparine
Drug: dalteparine (Fragmin)
transurethrals surgery with and without dalteparine
Other Name: Dlateparine=Fragmin
Placebo Comparator: B
NaCL 0.9%
Drug: dalteparine (Fragmin)
transurethrals surgery with and without dalteparine
Other Name: Dlateparine=Fragmin

Detailed Description:
The aim of our study is to proof that transurethral surgery under thrombophylaxis with dalteparine is safe. The study design is double-blind placebo controlled.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • transurethral surgery

Exclusion Criteria:

  • oral anticoagulation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00681785

Urologische Universitätsklinik beider Basel
Liestal, Switzerland, 4410
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Study Chair: Thomas C Gasser, Prof Department of Urology Liestal
  More Information

Responsible Party: Maurer Patrick, Dr, Department of Urology, Kantonsspital Liestal Identifier: NCT00681785     History of Changes
Other Study ID Numbers: 269/05
Study First Received: April 21, 2008
Last Updated: May 19, 2008

Keywords provided by University Hospital, Basel, Switzerland:
thrombophylaxis and transurethral surgery

Additional relevant MeSH terms:
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017